Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects

Phase 4 Completed 150 enrolled Certmedica International GmbH

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the effect on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 Kg/m2) and with weight \> 75 Kg/m2 being administered with a 3 g/day polyglucosamine dosage.

Timeline

Start: 2020-04-24
Primary completion: 2021-12-20
Completion: 2021-12-20

Publications

Rondanelli M, Perna S, Porta MD, Lombardoni F, Patelli Z, Nichetti M, Gasparri C, Pistolesi E, Cestaro B, Cazzola R. Modification of metabolic syndrome parameters following the administration of polyglucosamine L112: results of a subgroup analysis of subjects enrolled in a double blind randomised placebo controlled clinical investigation. BMC Nutr. 2025 Sep 2;11(1):170. doi: 10.1186/s40795-025-01153-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Polyglucosamine L112	Unknown	3 g	—

Indications

No indication recorded.